Pharmaceutical Industry Independence Strategy in Supporting Defense Economic Post-Covid-19

Authors

  • Risma Wati Isnaeniah Universitas Pertahanan
  • Lukman Yudho Prakoso Universitas Pertahanan
  • Guntur Eko Saputro Universitas Pertahanan

DOI:

https://doi.org/10.31851/jmksp.v8i2.11228

Keywords:

Covid-19, National Defense, Pharmaceutical Industry, Self-Reliance, Strategy

Abstract

This article talks about health is one type of non-military threat that can disrupt the stability of a country. This is evidenced by the Covid-19 pandemic which has had a domino effect on the economic, social, and political fields of all countries in the world, including Indonesia. This article found handling Covid-19 on the health side is the availability of health workers, medical devices, and medicines. One of the obstacles faced is the limited stock of drugs due to the stagnant supply of medicinal raw materials from abroad, while 90-95% of the medicinal raw materials used by the pharmaceutical industry are still imported. With this experience, the independence of the pharmaceutical industry must be achieved without depending on foreign countries and achieving domestic resilience. In achieving this, various obstacles and barriers must be faced by the government by setting the right strategies and policies. In addition, a collaboration between the government and the pharmaceutical industry is needed so that the implementation of realizing the independence of the pharmaceutical industry is achieved effectively and efficiently.

References

Antonakis, N., & Achilldelis, B. (2001). The dynamics of technological innovation: the case of the pharmaceutical industry. Research Policy, 30, 535-588.

Ministry of Industry. (2021). Membangun Kemandirian Industri Farmasi Nasional [Building the Independence of the National Pharmaceutical Industry]. Pusdatin Kemenperin.

Law No. 3 of 2002. Undang-Undang Nomor 3 Tahun 2002 tentang Pertahanan Negara

Law No. 36 of 2009. Undang-Undang Nomor 36 Tahun 2009 tentang Kesehatan

Malerba, F., & Orsinego, L. (2001). Innovation and Market Structure in the Dynamics of the Pharmaceutical Industry and Biotechnology: Towards a History Friendly Model, The DRUID Nelson and Winter Conference, Albo.

Mawarti, R. S. (2017). Prospek Industri Farmasi Di Indonesia [Prospects for the Pharmaceutical Industry in Indonesia]. Jurnal Inspirasi, 8(2),69-72. https://doi.org/10.35880/inspirasi.v8i2.105

Meliawati. (2020). Kebijakan Industri Farmasi pada Masa Pendemi Covid-19 [Pharmaceutical Industry Policy during the Covid-19 Pandemic]. Jurnal Farmasi Udayana, Vol 9, No 2, 2020, 2-82.

Minister of Health Regulation Number 17 of 2017 concerning Action Plan for the Development of the Pharmaceutical and Medical Device Industry

Regulation of Minister of Industry No. 16 of 2020

Ruskar, D., Hastuti, S., Wahyudi, H., Widana, I. D. K. K., & Apriyadi, R. K. (2021). Lafial: Pandemi Covid-19 sebagai momentum kemandirian industri farmasi menuju ketahanan kesehatan nasional [Lafial: The Covid-19 pandemic is a momentum for the independence of the pharmaceutical industry towards national health security]. PENDIPA Journal of Science Education, 5(3), 300-308.

Sampurno. (2017). Kapabilitas Teknologi dan Penguatan R&D: Tantangan Industri Farmasi Indonesia [Technology Capability and Strengthening R&D: Challenges for the Indonesian Pharmaceutical Industry]. Majalah Farmasi Indonesia, 18(4), 199-209.

Srinivasan. (2011). Medicines for All. The Pharma Industry and the Indian State. Economics and Political Weekly, June 11-17, 2011, Vol 46, No 24, 43-50.

Presidential Regulation No. 12 of 2021

Downloads

Published

2023-07-05

How to Cite

Isnaeniah, R. W., Prakoso, L. Y., & Saputro, G. E. (2023). Pharmaceutical Industry Independence Strategy in Supporting Defense Economic Post-Covid-19. JMKSP (Jurnal Manajemen, Kepemimpinan, Dan Supervisi Pendidikan), 8(2), 674–685. https://doi.org/10.31851/jmksp.v8i2.11228